Johnson & Johnson Adicet Bio, Inc. Transaction History
Johnson & Johnson
- $314 Million
- Q3 2024
A detailed history of Johnson & Johnson transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Johnson & Johnson holds 364,472 shares of ACET stock, worth $338,958. This represents 0.17% of its overall portfolio holdings.
Number of Shares
364,472
Previous 364,472
-0.0%
Holding current value
$338,958
Previous $441,000
18.82%
% of portfolio
0.17%
Previous 0.15%
Shares
2 transactions
Others Institutions Holding ACET
# of Institutions
72Shares Held
59.2MCall Options Held
4.2KPut Options Held
6.7K-
Orbimed Advisors LLC San Diego, CA11.4MShares$10.6 Million0.39% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$7.64 Million1.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$7.01 Million0.15% of portfolio
-
Goldman Sachs Group Inc New York, NY3.76MShares$3.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.21MShares$2.98 Million0.0% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $37.2M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...